<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02289339</url>
  </required_header>
  <id_info>
    <org_study_id>MucS001-14</org_study_id>
    <nct_id>NCT02289339</nct_id>
  </id_info>
  <brief_title>Everyday Practice With Transcatheter Aortic Valve Implantation</brief_title>
  <acronym>EVERY-TAVI</acronym>
  <official_title>Experience With Percutaneous Transcatheter Aortic Valve Implantation in Patients With Symptomatic Aortic Valve Disease in Two German Centers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum der Universitaet Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinikum der Universitaet Muenchen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry is to document the everyday practice in our centers with minimal
      invasive treatment of patients with aortic valve disease who were considered suitable for
      transfemoral aortic valve implantation by heart team.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The TAVI program in our center started on November 2007. As part of the national policy for
      quality assurance in medicine a detailed clinical characterization of the TAVI-population was
      required. Furthermore, a detailed description of the procedure and peri-procedural
      complications until discharge was required. In our center we designed and are routinely using
      a TAVI database which fulfills the authority requirements as well as has additional data
      needed for planning and documentation of TAVI procedure. Since there is already a
      considerable number of TAVI patients in this database we aim to perform statistical analyses
      answering different question in this filed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2007</start_date>
  <completion_date type="Actual">May 20, 2018</completion_date>
  <primary_completion_date type="Actual">April 20, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of post-TAVI aortic regurgitation</measure>
    <time_frame>30 days</time_frame>
    <description>echocardiographicall and angiographycally determined</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of bleeding complications</measure>
    <time_frame>30 days</time_frame>
    <description>defined according to BARC and VARC-2 classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>30 days</time_frame>
    <description>all-cause and cardio/cerebrovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality rate</measure>
    <time_frame>2-years</time_frame>
    <description>all-cause and cardio/cerebrovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality rate</measure>
    <time_frame>5-years</time_frame>
    <description>all-cause and cardio/cerebrovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of cerebrovascular events</measure>
    <time_frame>30 days</time_frame>
    <description>stroke or TIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of cerebrovascular events</measure>
    <time_frame>2-years</time_frame>
    <description>stroke or TIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of cerebrovascular events</measure>
    <time_frame>5-years</time_frame>
    <description>stroke or TIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of new pacemaker implantation</measure>
    <time_frame>30-day</time_frame>
    <description>pacemaker after TAVI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of new pacemaker implantation</measure>
    <time_frame>1-year</time_frame>
    <description>pacemaker after TAVI</description>
  </secondary_outcome>
  <other_outcome>
    <measure>incidence of vascular complications</measure>
    <time_frame>30 days</time_frame>
    <description>defined according to VARC-2 classification</description>
  </other_outcome>
  <other_outcome>
    <measure>incidence of re-hospitalisation</measure>
    <time_frame>2-year</time_frame>
    <description>new unplanned hospital stay due to cardiovascular und cerebrovascular reasons</description>
  </other_outcome>
  <other_outcome>
    <measure>incidence of re-hospitalisation</measure>
    <time_frame>5-year</time_frame>
    <description>new unplanned hospital stay due to cardiovascular und cerebrovascular reasons</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2370</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>TAVI patients</arm_group_label>
    <description>all patients undergoing transcatheter aortic valve prostheses implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>aortic valve prostheses</intervention_name>
    <description>balloon-expandable and self-expandable aortic valve prostheses</description>
    <arm_group_label>TAVI patients</arm_group_label>
    <other_name>CoreValve, CoreValveE, Sapien XT, Sapien S3, Lotus</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with aortic valve stenosis suitable for transfemoral transcatheter aortic valve
        implanation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aortic stenosis

          -  Intermediate-to-high risk for surgery

          -  Heart team decision

        Exclusion Criteria:

          -  Contraindication to transfemoral TAVI procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julinda Mehilli, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology Department, Munich University Clinic, Ludwig-Maximilian University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steffen Massberg, Prof. MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiology Department, Munich University Clinic, Ludwig-Maximilian University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology Department, Segeberger Kliniken</name>
      <address>
        <city>Bad Segeberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology, Munich University Clinic, Ludwig-Maximilian University</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Jochheim D, Zadrozny M, Ricard I, Sadry TM, Theiss H, Baquet M, Schwarz F, Bauer A, Khandoga A, Sadoni S, Pichlmaier M, Hausleiter J, Hagl C, Massberg S, Mehilli J. Predictors of cerebrovascular events at mid-term after transcatheter aortic valve implantation - Results from EVERY-TAVI registry. Int J Cardiol. 2017 Oct 1;244:106-111. doi: 10.1016/j.ijcard.2017.03.003.</citation>
    <PMID>28784441</PMID>
  </results_reference>
  <results_reference>
    <citation>Mehilli J, Jochheim D, Abdel-Wahab M, Rizas KD, Theiss H, Spenkuch N, Zadrozny M, Baquet M, El-Mawardy M, Sato T, Lange P, Kuppatt C, Greif M, Hausleiter J, Bauer A, Schwarz F, Pichlmaier M, Hagl C, Richardt G, Massberg S. One-year outcomes with two suture-mediated closure devices to achieve access-site haemostasis following transfemoral transcatheter aortic valve implantation. EuroIntervention. 2016 Nov 20;12(10):1298-1304. doi: 10.4244/EIJV12I10A213.</citation>
    <PMID>27866140</PMID>
  </results_reference>
  <results_reference>
    <citation>Hein-Rothweiler R, Jochheim D, Rizas K, Egger A, Theiss H, Bauer A, Massberg S, Mehilli J. Aortic annulus to left coronary distance as a predictor for persistent left bundle branch block after TAVI. Catheter Cardiovasc Interv. 2017 Mar 1;89(4):E162-E168. doi: 10.1002/ccd.26503. Epub 2016 Apr 1.</citation>
    <PMID>27038099</PMID>
  </results_reference>
  <results_reference>
    <citation>Jochheim D, Zadrozny M, Theiss H, Baquet M, Maimer-Rodrigues F, Bauer A, Lange P, Greif M, Kupatt C, Hausleiter J, Hagl C, Massberg S, Mehilli J. Aortic regurgitation with second versus third-generation balloon-expandable prostheses in patients undergoing transcatheter aortic valve implantation. EuroIntervention. 2015 Jun;11(2):214-20. doi: 10.4244/EIJV11I2A40.</citation>
    <PMID>26093840</PMID>
  </results_reference>
  <results_reference>
    <citation>Jochheim D, Abdel-Wahab M, Mehilli J, Ellert J, WÃ¼bken-Kleinfeld N, El-Mawardy M, Pache J, Massberg S, Kastrati A, Richardt G. Significant aortic regurgitation after transfemoral aortic valve implantation: patients' gender as independent risk factor. Minerva Cardioangiol. 2015 Oct;63(5):371-9. Epub 2015 Mar 27.</citation>
    <PMID>25812583</PMID>
  </results_reference>
  <results_reference>
    <citation>Jochheim D, Schneider VS, Schwarz F, Kupatt C, Lange P, Reiser M, Massberg S, GutiÃ©rrez-Chico JL, Mehilli J, Becker HC. Contrast-induced acute kidney injury after computed tomography prior to transcatheter aortic valve implantation. Clin Radiol. 2014 Oct;69(10):1034-8. doi: 10.1016/j.crad.2014.05.106. Epub 2014 Jul 10.</citation>
    <PMID>25017451</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>November 8, 2014</study_first_submitted>
  <study_first_submitted_qc>November 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2014</study_first_posted>
  <last_update_submitted>August 9, 2018</last_update_submitted>
  <last_update_submitted_qc>August 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum der Universitaet Muenchen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Julinda Mehilli</investigator_full_name>
    <investigator_title>Prof. MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

